RFQ Attachment 3 - QA.pdf
PDF 324 KB Posted
- Solicitation number
- RFQ-NIAID-24-2226993
About this file
This document is a Request for Quotation (RFQ) for Histopathology Services to Support On-going Small Animal Product Efficacy Studies for Viruses with Pandemic Potential. The National Institute of Allergy and Infectious Diseases (NIAID) is seeking commercial veterinary histopathology services to prepare slides, evaluate and interpret slides, capture photomicrographs, and generate reports to support product efficacy testing. The RFQ includes a base period of performance from September 23, 2024 to September 22, 2025 with option periods available. Interested vendors must submit quotes by 3:00pm ET on September 13, 2024. Award will be made on a firm-fixed-price basis to the responsible offeror that provides the best value based on technical capability, past performance, and price. The RFQ includes details on the scope of work, evaluation criteria, and applicable FAR provisions and clauses.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| RFQ Attachment 3 - QA.pdf | ||
| RFQ Attachment 3 - QA.pdf | ||
| RFQ Attachment 1 - SOW.pdf | ||
| RFQ Attachment 2 - FAR 52.212-5 Full Text.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Histopathology Services to Support On-going Small Animal Product Efficacy Studies for Viruses with Pandemic Potential
Notice ID: RFQ-NIAID-24-2226993
RFQ Attachment 3 – Questions & Answers
9/4/2024 – Amendment 1
Q1. Could you please elaborate on the lead time we would receive between notification and receipt of each potential study (e.g., 2 weeks, 1 month, etc.)?
A1. We anticipate the lead time to be 2 weeks.
Q2. For forecasting purposes, do you have an idea of how frequently we could receive new studies?
Could it be in batches, or would there be a staggered approach to study shipments?
A2. The vendor may receive more than one study within a short period. However, the Government will prioritize the studies, and there is no expectation that multiple studies must be completed simultaneously.
9/10/2024 – Amendment 2
Q3. Current practices may generate more than 4 slides for a representative histopathologic examination if all target tissues noted within the request (lung, liver, spleen, brain) are submitted for histologic processing. This is especially true for rats or similarly sized laboratory animals (e.g.
up to 7 slides). Is such variance acceptable?
A3. Offerors must adhere to the 4 slides per animal requirement detailed in the Statement of Work.
Addition (9/12/2024): Mounting multiple sections on a single slide is permissible.
File details come from the government source that posted it. Updated .